Skip to content
Screener

BillionToOne, Inc. BLLN Clinical trial support and other services — Revenue

Other product segments

Prenatal
$94.25M+54.9%
Oncology
$13.66M+176%

Similar metrics at other companies

Protagonist Therapeutics logo
PTGXFusfertide Clinical Trial Supplies — Revenue
$11M
Henry (Jack) & Associates logo
JKHYServices and Support — Revenue
$365.15M+10.4%
Maximus logo
MMSClinical Services — Revenue
$553.08M-1.3%
ADTRAN Holdings, Inc. logo
ADTNServices And Support — Revenue
$48.15M+5.8%
Neuronetics logo
STIMClinical Services — Revenue
$21.53M+15.4%
Allison Transmission Holdings logo
ALSNService Parts Support Equipment And Other — Revenue
$177M+0.6%

Other financials

Income statement

See full
Revenue$109.4M+64.4%
Gross profit$77.1M+77.4%
Operating income$5.5M+438%
Net income$8.1M+3,374%
EPS (diluted)$0.15+850%

Balance sheet

See full
Cash & equivalents$548.6M+190%
Total debt$143.9M
Total equity$536.8M+315%
Total assets$729.7M

Cash flow

See full
Operating cash flow$9.1M+673%
CapEx$4.0M+40.9%
Free cash flow$5.1M+401%

Valuation

See full
Market cap$4.32B-1.8%
Enterprise value$3.92B
P/E114.7×
P/S10.9×

Profitability

See full
Gross margin71.3%+10.3pp
Operating margin10.9%+7.0pp
Net margin9.5%+5.9pp
FCF margin8.3%

Returns & leverage

See full
Return on equity26.3%
Debt / equity0.3×
Current ratio11.7×

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BillionToOne, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:42 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0002070849-26-000050
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Prenatal$94,248$60,852$190,773$116,929
Oncology13,6634,94724,3837,123
Clinical trial support and other services1,5377742,6801,484
Total revenues$109,448$66,573$217,836$125,536

Item 1. Financial Statements (Unaudited)

FAQ

What is BillionToOne, Inc.'s clinical trial support and other services — revenue?
BillionToOne, Inc. (BLLN) reported clinical trial support and other services — revenue of $1.54M in Q2 2026.
How has BillionToOne, Inc.'s clinical trial support and other services — revenue changed year-over-year?
BillionToOne, Inc.'s clinical trial support and other services — revenue increased by 98.6% year-over-year, from $774K to $1.54M.
What does clinical trial support and other services — revenue mean?
This metric represents the total revenue generated from providing specialized support services to clinical trials and other ancillary diagnostic service offerings. It reflects the company's ability to monetize its molecular counting platform and diagnostic expertise through partnerships with pharmaceutical or research organizations. This revenue stream serves as an indicator of the company's diversification beyond core diagnostic product sales and its integration into the broader clinical research ecosystem.

Ask your AI about BillionToOne, Inc.'s clinical trial support and other services — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude